CD5-positiverituximab背景:濔漫性大B細胞淋巴瘤(diffuse large B-cell lymphoma, DLBCL)是最常見的非何杰金氏淋巴瘤,且也是一個由多種疾病所組成的一群疾病。案例描述:在此,我們報告一位罹患「原發性CD5陽性濔漫性大B細胞淋巴瘤」(de novo CD5-positive DLBCL)的病人,以右側骼骨附近、右側鼠蹊部附...
Ann Arbor分期Ⅲ~Ⅳ期、存在大包块及未接受≥4个周期鞘内注射是初诊CD5阳性DLBCL患者预后的独立危险因素。 关键词: 淋巴瘤,大B细胞,弥漫性;CD5抗原;疾病特征;预后 ABSTRACT ObjectiveTo explore the clinical characteristics and prognosis of newly diagnosed CD5-positive diffuse large B-cell lymphoma (DLBCL)...
一般来说,EBV阳性淋巴瘤患者的预后比EBV阴性淋巴瘤患者差。与EBV阴性的cHL患者相比,EBV阳性cHL患者的3年无事件生存(EFS)和OS率更差。此外,EBV感染在DLBCL中与年龄增长及疾病晚期正相关,而在CLL中则预示着更短的治疗反应时间和更低...
The total effective rate was significantly higher in the negative group than in the positive group, with a statistical difference (P<0.05). ConclusionThe pathological features in the patients with DLBCL positive in CD5 are quite different from those of the patients negative in CD5 and the ...
CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-).acute myeloid leukemia... N Yokose,Y Shioi,Y Sugisaki,... - 《Leukemia & Lymphoma》 被引量: 3发表: 2006年 CD20-negative large-cell lymphoma with plasmablastic features: a clinic...
Patients diagnosed as diffuse large B cell lymphoma (DLBCL) with CD5 positive normally have a worse outcome and poorly respond to the regulatory treatment strategy. We recently reported differently expressed tRFs and their potential target-genes of tRFs
目的:研究原发 CD5阳性弥漫大 B 细胞淋巴瘤(CD5-positive diffuse large B cell lymphoma,CD5+DLBCL)的临床,免疫表型,细胞遗传学特点及治疗反应和预后.方法:回顾分析7例通过免疫组化和流式细胞免疫分析确诊的 CD5+DLBCL 的临床和免疫表型特点,细胞遗传学异常及治疗和预后.结果:7例患者中位年龄70岁.3例以淋巴...
of MYC/BCL2 was also a poor prognostic factor for DLBCL.Most studies had found that DLBCL patients with primary CD5 positive had a poor prognosis, so it is necessary to fully investigate biomarkers related with DLBCL for risk stratification, prognosis analysis and treatment guidance of patients....
目的探讨C-MYC、bcl-2、bcl-6蛋白的表达与原发性CD5阳性的弥漫性大B细胞淋巴瘤(CD5-positive diffuse large B cell lymphoma, CD5+DLBCL)患者临床病理特征之间的关系。方法收集2013年2月至2018年9月上海交通大学医学院附属瑞金医院初治诊断为原发性CD5+DLBCL标本57例, 采用HE染色、免疫组织化学技术及荧光原...
第一部分:基于倾向性评分匹配探究CD5阳性弥漫大B细胞淋巴瘤的生存预后 【研究目的】 通过倾向性评分匹配消除混杂因素,探究CD5阳性弥漫大B细胞淋巴瘤(CD5-positive diffuse large B cell lymphoma,CD5+DLBCL)的生存预后. 【研究方法】 收集600例2011年10月至2023年4月我院病理科初诊为DLBCL患者的临床病理资料,其中...